Cargando…
Non-clinical development of CER-001
Cardiovascular disease remains the most pressing healthcare issue for the developed world and is becoming so for developing countries. There are no currently approved therapies that can rapidly reduce the burden of unstable, inflamed plaque in the overall coronary vascular bed. High-density lipoprot...
Autor principal: | Barbaras, Ronald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594020/ https://www.ncbi.nlm.nih.gov/pubmed/26500552 http://dx.doi.org/10.3389/fphar.2015.00220 |
Ejemplares similares
-
Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings
por: Keyserling, Constance H., et al.
Publicado: (2017) -
HDL and CER-001 Inverse-Dose Dependent Inhibition of Atherosclerotic Plaque Formation in apoE(-/-) Mice: Evidence of ABCA1 Down-Regulation
por: Tardy, Claudine, et al.
Publicado: (2015) -
Beneficial effects of recombinant CER-001 high-density lipoprotein infusion in sepsis: results from a bench to bedside translational research project
por: Stasi, Alessandra, et al.
Publicado: (2023) -
The HDL mimetic CER‐001 remodels plasma lipoproteins and reduces kidney lipid deposits in inherited lecithin:cholesterol acyltransferase deficiency
por: Pavanello, Chiara, et al.
Publicado: (2021) -
Comparative Effectiveness Research (CER): A Summary of AHRQ’s CER on Therapies for Rheumatoid Arthritis
por: Oderda, Gary M., et al.
Publicado: (2011)